{"id":"NCT00857415","sponsor":"Avid Radiopharmaceuticals","briefTitle":"Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain","officialTitle":"A Phase III Study of the Correlation Between Florbetapir F 18 (18F-AV-45) PET Imaging and Amyloid Pathology","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-03","completion":"2010-05","firstPosted":"2009-03-06","resultsPosted":"2012-05-07","lastUpdate":"2012-05-22"},"enrollment":226,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"SINGLE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"florbetapir F 18","otherNames":["18F-AV-45","AV-45","Amyvid"]}],"arms":[{"label":"Autopsy Cohort","type":"EXPERIMENTAL"},{"label":"Specificity Cohort","type":"EXPERIMENTAL"}],"summary":"The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).","primaryOutcome":{"measure":"Correlation of Florbetapir-PET Image and Amyloid Plaque Density","timeFrame":"at autopsy up to 12 months post-scan","effectByArm":[{"arm":"Autopsy Cohort","deltaMin":0.78,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":["21245183","22749065"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":152},"commonTop":["Headache"]}}